Fluarix (trivalent inactivated “split virus” influenza vaccine [Types A and B], from GlaxoSmithKline) has been approved for use in children 3–17 years of age. This approval was based on data from a study comparing 2,115 children who received Fluarix with 1,210 children who received Fluzone (trivalent inactivated influenza subvirion vaccine [Types A and B], from sanofi pasteur), approved for use in children ≥6 months of age. Results showed that children ≥3 years old vaccinated with Fluarix and Fluzone produced similar amounts of antibodies in the blood at levels considered likely to be protective against seasonal influenza.
Fluarix is already indicated for influenza immunization in adults ≥18 years of age.
For more information call (888) 825-5249 or visit www.gsk.com.